Brenda Eap, PhD @beappbeapp

@theA4LI We now have hundreds of companies working on targeting the biology of aging and now with @ARPA_H PROSPR working on intrinsic capacity, incorporating this would be so timely.

Last chance and we mean it!!!!

The Alliance for Longevity Initiatives (A4LI) @theA4LI

2 weeks ago

This is your final invitation to join us at the H-SPAN Summit D.C. Registration closes this week. If you are serious about the future of longevity, this is the one event you don't want to miss. Here is a snapshot of the schedule you're about to miss out on: 📅 Day 1:

3 7 21 1K 0

@KrisMBarnes Well said!

Our H-SPAN Summit DC is just around the corner. This year, we’re building on last year’s conversation about cross-agency alignment in funding and regulatory frameworks for longevity. We are thrilled to close Day 2 of the Summit with a landmark session: “Building the Framework: Policy Levers for Longevity Innovation.” For the first time, senior administration leaders and Members of Congress will join in a singular forum to discuss current federal initiatives and legislative levers that set out to make healthy longevity a national priority and achieve a true "longevity dividend." Featured speakers for this policy-focused second day include: •Dr. Mehmet Oz (Tentative), Administrator of the Centers for Medicare & Medicaid Services (CMS) •Lowell M. Zeta, Acting Chief of Staff and Deputy Commissioner for Strategic Initiatives, U.S. Food and Drug Administration (FDA) •Dr. Alicia Jackson, Director of the Advanced Research Projects Agency for Health (ARPA-H) •Congressman Kevin Mullin (CA-14), Representative of the Bay Area Longevity Biotech Ecosystem •Congressman Jim McGovern (MA-2), Ranking Member of the House Rules Committee and Champion for Nutrition and Healthy Aging Policy •Congressman Paul Tonko (NY-20), Co-chair of the Congressional Longevity Science Caucus

Russia has committed $26 billion to longevity science, while China is advancing large-scale stem cell anti-aging trials and expanding aggressive investment in regenerative medicine and longevity biotechnology. Scientific leadership in longevity is rapidly becoming a defining frontier of global competitiveness. The United States cannot afford to sit on the sidelines. Join our letter campaign: actionnetwork.org/letters/the-us…

A positive signal that the longevity ecosystem is gaining the critical visibility it needs from state lawmakers. Excited to get started!

The Alliance for Longevity Initiatives (A4LI) @theA4LI

3 weeks ago

What an unforgettable day! Yesterday marked a monumental win for the geroscience field and the longevity industry. California Senate Resolution 104 passed the floor with a unanimous 35-0 vote! Joining the presentation on the Senate floor were Dylan Livingston (Founder and CEO of

keyboard_arrow_left Previous keyboard_arrow_right Next

6 8 27 2K 1

HB 1735 has passed the New Hampshire Senate. The bill was amended during the legislative process, but its passage reflects growing recognition that patients and innovators deserve greater flexibility when pursuing promising longevity therapies. "The final bill is more limited than we originally hoped for, but it's encouraging to see states like New Hampshire continue engaging with these issues,” said Dylan V. Livingston, Founder and CEO of @theA4LI. “The reality is that patients are looking for more options, and policymakers across the country are increasingly willing to have that conversation." We are grateful to the many New Hampshire leaders who championed HB 1735, including Governor @KellyAyotte and @NHSpeaker Sherman Packard. We also extend our thanks to the stakeholders, advocates, and volunteers who dedicated their time and energy to supporting the legislation and advancing the conversation around patient access and medical innovation.

This resolution is a positive signal that the longevity ecosystem in CA is gaining critical visibility it needs!

The Alliance for Longevity Initiatives (A4LI) @theA4LI

4 weeks ago

On June 8th, A4LI and a strong representation of academic and biotechnology leaders in longevity will join CA Senator Josh Becker (@SenJoshBecker) as he presents Senate Resolution 104. SR 104 advocates for a fundamental shift in how California approaches public health and fiscal

5 9 22 729 1

@theA4LI @JayRoshe5 @SenJoshBecker This is a huge win for the field and for CA!!

@theA4LI Stellar lineup indeed! We have a few more announcements coming! 😏

If you’re interested in attending, please reach out. This is the year to be in DC, and your presence and voice are incredibly important!

The Alliance for Longevity Initiatives (A4LI) @theA4LI

a month ago

The H-SPAN Summit D.C. is only ONE MONTH away! Join us as we bring together researchers, policymakers, innovators, and advocates working to accelerate progress against age-related diseases and advance the future of medicine. Registration and Agenda Here:

5 7 26 799 0

Thank you for highlighting the momentum we have been building since our inaugural event in 2024, @LongevityTech! Incredible to see how far the conversation has moved from speculative science to serious national policy in just three years. Read it here: longevity.technology/news/h-span-re… @bioagelabs @RetroBio_ @KarlPfleger @soniaarrison @mkaeberlein @DrMikeRoizen @BuckInstitute @aubreydegrey

This is the most ambitious agenda we’ve put together so far!

The Alliance for Longevity Initiatives (A4LI) @theA4LI

a month ago

Hosting our Summit at Georgetown University’s Capitol Campus allows us to do so much more! We will have quick pitches, workshops, and a poster session for everyone to participate in! Check out the full schedule and get your ticket today: a4li.org/h-span-summit-…

2 6 19 1K 0

I’m thrilled to announce my new podcast, Longevity Science with Matt Kaeberlein. Episode 1 is now live and takes a deep dive into the story of dinitrophenol (DNP) — an experimental weight loss drug linked to hundreds of deaths and a cautionary reminder of what can happen when enthusiasm for new therapies gets ahead of the science. Episode 2 drops Friday and features a Longevity Roundtable with @BKennedy_aging and @docmranney . We discuss proactive healthcare, rapamycin, peptides, epigenetic reprogramming, biological age testing, and where the field of longevity medicine may be headed next. My goal with this channel is simple: thoughtful, evidence-based conversations that separate signal from noise in the rapidly evolving world of longevity science. I hope you’ll check it out — and subscribe on YouTube, Spotify, or wherever you listen to podcasts. YouTube: youtube.com/@mkaeberlein Spotify: open.spotify.com/show/7DRRH5lfL…

The passage of HB 1734 and HB 1735 is a no-brainer, and it is disappointing how much pushback it is receiving from the “pro-business,” “pro-freedom” and “pro-life” Republicans on the Senate Health and Human Services Committee. There are countless lives that can be helped — from early stage chronic disease to rare disease patients, all of whom have no other options. If you live in NH, call your Senators and demand these bills get passed. If you know someone in NH, do the same. @KellyAyotte — thank you for your support, your leadership, and your ability to see things clearly and with reason. @roche4nh — you are making lives worse and actively hurting your state. As a pharmacist, you of all people should understand what’s at stake for patients who have run out of options. You still have a chance to get this right. Do the right thing.

Adam Sexton @AdamSextonWMUR

a month ago

Gov. @KellyAyotte tells reporters she is supportive of bills moving forward in the legislature to expand right-to-try & expanded experimental access in New Hampshire. Supporters contend these bills could provide a biotech economic boost for the state. #NHPolitics #WMUR

14 13 105 27K 4

The Alliance for Longevity Initiatives (A4LI) would like to provide an update regarding New Hampshire’s ongoing efforts to expand patient access to investigational medical treatments and strengthen the state’s position as a hub for biomedical innovation. This week, legislative language from HB1734 and HB1735 was successfully attached to SB504 through the amendment process in the New Hampshire House of Representatives, keeping these reforms active as negotiations continue. HB1734 would authorize the establishment of experimental treatment centers capable of offering eligible investigational therapies under state oversight, while HB1735 would expand New Hampshire’s Right to Try framework to include patients suffering from chronic and debilitating conditions We would especially like to thank House Speaker Sherman Packard (@NHSpeaker) and Majority Leader Jason Osborne (@Osborne4NH) for their leadership and continued support. Together, these proposals continue New Hampshire’s emergence as one of the most forward-looking states in the country on medical innovation, patient autonomy, and access to next-generation therapies. As the process continues, we encourage everyone to respectfully reach out to Senate President Sharon Carson, Senator Rochefort, and Senator Birdsell and urge them to support SB504 as amended during committee of conference negotiations. We look forward to continuing to work with lawmakers, patients, advocates, and innovators as this effort progresses.

@KrisMBarnes I agree!!

𝐖𝐞 𝐚𝐫𝐞 𝐥𝐢𝐯𝐢𝐧𝐠 𝐥𝐨𝐧𝐠𝐞𝐫, 𝐛𝐮𝐭 𝐰𝐞 𝐚𝐫𝐞𝐧'𝐭 𝐥𝐢𝐯𝐢𝐧𝐠 𝐡𝐞𝐚𝐥𝐭𝐡𝐢𝐞𝐫. Sixty percent of the global disease burden is now tied to chronic, age-related conditions. We are trading quick deaths for decades of disability, and it’s time for the NIH to fund the solution, not just manage the decline. As the NIH requests input for its Strategic Plan for FY 2027-2031, the Alliance for Longevity Initiatives is proposing a Disease-Burden Framework. Our proposal recommends that research funding be allocated by actual disease burden, measured by DALYs (Disability-Adjusted Life Years) from the Global Burden of Disease Study. This isn't a new concept—a framework like this already exists with the Onco-Aging Consortium within the NCI and NIA. Now, it’s time to expand this successful model across all major disease institutes—NHLBI, NIDDK, NEI, NINDS, and NIDCD. 𝐖𝐡𝐢𝐜𝐡 𝐢𝐧𝐬𝐭𝐢𝐭𝐮𝐭𝐞 𝐝𝐨 𝐲𝐨𝐮 𝐭𝐡𝐢𝐧𝐤 𝐰𝐨𝐮𝐥𝐝 𝐛𝐞𝐧𝐞𝐟𝐢𝐭 𝐦𝐨𝐬𝐭 𝐟𝐫𝐨𝐦 𝐚 𝐟𝐨𝐫𝐦𝐚𝐥 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐍𝐈𝐀? 𝐋𝐞𝐭'𝐬 𝐝𝐢𝐬𝐜𝐮𝐬𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐦𝐞𝐧𝐭𝐬. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐩𝐫𝐨𝐩𝐨𝐬𝐚𝐥 𝐚𝐧𝐝 𝐬𝐢𝐠𝐧 𝐨𝐧 𝐲𝐨𝐮𝐫 𝐬𝐮𝐩𝐩𝐨𝐫𝐭: 🔗actionnetwork.org/petitions/real…

@theA4LI Institutes like the NEI and NIDCD play an understated yet critical role in longevity. These institutes protect the sensory inputs that define our quality of life and we often take them for granted, so I'm excited and very supportive of these consortia with the NIA!

@theA4LI @US_FDA Really looking forward to this panel with @bioagelabs and Kitalys!